MedTrace Logo

Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus

NCT02656082 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2019-02-27

No results posted yet for this study

Summary

The purpose of this study is to determine whether Etanercept which is given through intradermal injection is effective in the treatment of discoid lupus erythematosus (DLE).

The investigators also would like to develop new tests to measure skin inflammation by scanning the affected skin using optical coherence tomography (OCT), thermography and laser doppler imaging (LDI) and taking photographs of the rash (to be done before and after treatment). If the findings from these new tests are similar to the ones from taking a sample of skin (biopsy), then the latter (which is an invasive test) can be avoided.

Conditions

  • Lupus Erythematosus, Discoid
  • Lupus Erythematosus, Cutaneous
  • Lupus Erythematosus, Chronic Cutaneous

Interventions

DRUG

Etanercept

Treatment with etanercept is intended for remission induction of DLE only and not for maintenance purpose.

Sponsors & Collaborators

  • National Institute for Health Research, United Kingdom

    collaborator OTHER_GOV

  • Pfizer

    collaborator INDUSTRY

  • Clinical Trials Research Unit, Leeds

    collaborator UNKNOWN

  • University of Leeds

    lead OTHER

Principal Investigators

  • Paul Emery, MD FMedSci · University of Leeds

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-01
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02656082 on ClinicalTrials.gov